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Introduction
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune 
disease characterized by salivary and lachrymal glands dysfunction and 
inflammation, resulting in severe dry eye and dry mouth. During the 
last few years, mainly due to the advances of emerging high throughput 
genomic and proteomic technologies, several efforts have been made 
in searching for novel diagnostic and therapeutic biomarkers for pSS 
ultimately paving the way to the development of new concepts for 
therapies [1,2]. At present, the most consistent “–omics” data are those 
related to the identification of proteomic biomarkers for pSS in human 
saliva [3-5]. Saliva has been recognized as an attractive biological 
fluid for pSS since it may closely reflect the underlying glandular 
autoimmune exocrinopathy and can be repeatedly collected in a non-
invasive manner. A number of inflammatory and salivary epithelial 
proteins have been seen as potential biomarkers for the disease [6-
11]. Among those putative proteomic salivary biomarkers for pSS, 
we have developed a specific interest for gross cystic disease fluid 
protein-15/prolactin-inducible protein (GCDFP-15/PIP), a secretory 
acinar protein of 14KDa that has been identified as significantly under-
expressed in salivary samples of pSS patients in comparison to healthy 
volunteers in previous studies carried out by our and other groups [6-
9]. Although the function of GCDFP-15/PIP remains unknown, it has 
been reported that GCDFP-15/PIP binds to many proteins, including 
*Corresponding author: Gallo Alessia, 10 Center Drive, Rm 1N110, Bethesda, MD, 
USA, 20892, Tel: 301-594-1652; Fax: 301-402-1228; E-mail: alessia.gallo@nih.gov
Received May 06, 2013; Accepted June 12, 2013; Published June 15, 2013
Citation: Gallo A, Martini D, Sernissi F, Giacomelli C, Pepe P, et al. (2013) Gross 
Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible Protein (PIP) as 
Functional Salivary Biomarker for Primary Sjögren’s Syndrome. J Genet Syndr 
Gene Ther 4: 140. doi:10.4172/2157-7412.1000140
Copyright: © 2013 Gallo A, et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Gross Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible 
Protein (PIP) as Functional Salivary Biomarker for Primary Sjögren’s 
Syndrome 
Gallo A1*, Martini D2, Sernissi F2, Giacomelli C2, Pepe P2, Rossi C2, Riveros PP1, Mosca M2, Alevizos I1 and Baldini C2
1Sjögren’s  Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National 
Institutes of Health, USA
2Rheumatology Unit, University of Pisa, Italy via Roma 67, 56126, Pisa, Italy
Abstract
Background: Gross cystic disease fluid protein-15(GCDFP-15)/prolactin-inducible protein (PIP) is a secretory 
acinar glycoprotein of 14 KDa which we have recently described as significantly lower in salivary samples of patients 
with primary Sjögren’s syndrome (pSS) in comparison to healthy volunteers by proteomic analysis. 
Aims of the study: (1) to validate our previous data on the decrease of GCDFP-15/PIP protein in a larger 
number of subjects with pSS (2) to integrate the proteomic results with complementary immunoassays in order 
to better clarify the pathophysiological relevance of GCDFP-15/PIP in pSS exocrinopathy (3) to assess both the 
glandular expression of the GCDFP-15/PIP and the levels of glandular GCDFP-15/PIP mRNA in the patients’ minor 
salivary gland (MSG) biopsies in order to verify whether the observed reduction of GCDFP-15/PIP in saliva may be 
related to a decrease in the protein production. 
Patients and methods: A total of 123 salivary samples from patients affected by pSS, no-SS sicca syndrome 
and sex- age-matched healthy volunteers were analyzed by different proteomic techniques (SELDI-TOF-MS, 2DE, 
MALDI-TOF-MS). The expression of GCDFP-15/PIP was then validated by western blot analysis. Real Time PCR 
and immunohistochemistry for GCDFP-15/PIP in the minor salivary glands (MSG) biopsies were then carried out.
Results: By using complementary proteomic analysis we found that a putative peak of 16547 m/z was among 
the best independent biomarkers for pSS able to discriminate between patients and healthy controls with a 
sensitivity of 96 % and a specificity of 70%, with a global cross validated error of 29%. We identified the peak as 
the GCDFP-15/PIP protein and verified that the intensity of GCDFP-15/PIP was significantly lower in pSS patients 
when compared to both no-SS sicca subjects and healthy controls (p<0.0001). GCDFP-15/PIP expression also 
correlated with both the salivary flow rate (r=0.312, p=0.023) and MSG biopsies focus score (r=-0.377, p=0.04). 
Finally, immunohistochemistry confirmed that GCDFP-15/PIP staining was faint in mucus acini and Real Time PCR 
showed that GCDFP-15/PIP mRNA was significantly lower in pSS patients when compared to both no-SS sicca 
subjects and healthy controls (p=0.023) thus supporting the hypothesis that the observed reduction of GCDFP-15/
PIP in pSS saliva may be related to a decrease in the protein production. 
Conclusion: In this study by different complementary-omic techniques we confirmed the potential role of 
GCDFP-15/PIP as a novel biomarker for pSS. This finding might also be functionally important as GCDFP-15/PIP 
has previously been shown to bind to Aquaporin 5 (AQP5), a salivary gland water channel, critical to saliva formation 
that is known to be downregulated in pSS. It is likely that exploring the GCDFP-15/PIP/AQP5 axis will help better 
understand the mechanism of salivary gland dysfunction in pSS.
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fibrinogen, actin, keratin, myosin, and also the CD4 molecule of T 
cells, thus inhibiting T-lymphocyte apoptosis [12]. In addition, recent 
observations in mouse models for pSS have shown that GCDFP-15/
PIP may also bind to the C-terminal portion of aquaporin-5 (AQP5) 
leading to its physiological translocation from cytoplasm to the apical 
membrane of lachrymal glands [13]. Thus, an aberrant expression of 
GCDFP-15/PIP might negatively affect the trafficking of AQP5 from the 
cytoplasm to the membrane of the acinar cells subsequently interfering 
with the glandular secretion processes in salivary and lachrymal 
glands. The relevance of exploring the GCDFP-15/PIP/AQP5 axis in 
pSS hyposalivation might be foresee considering that for the past 15 
years, our laboratory has studied the value of developing a gene transfer 
approach, using the Aquaporin family of genes to restore salivary flow 
in patients with radiation-damaged salivary glands [14-16].
The aim of this study was therefore first to validate our previous data 
on the decrease of GCDFP-15/PIP in a larger number of subjects with 
pSS and second, to integrate the proteomic results with complementary 
immunoassays in order to better clarify the pathophysiological 
relevance of GCDFP-15/PIP in pSS exocrinopathy. More specifically, 
we correlated salivary GCDFP-15/PIP levels with patients’ salivary 
flow and minor salivary gland lymphocytic infiltration,  in order to 
explore if GCDFP-15/PIP reduction reflects the functional impairment 
of the salivary secretion process. We also assessed both the glandular 
expression of the GCDFP-15/PIP and the levels of glandular GCDFP-15/
PIP mRNA in minor salivary gland (MSG) biopsies in order to verify 
whether the observed reduction of GCDFP-15/PIP in saliva may be 
related to a decrease in the protein production. Ultimately, exploring 
the GCDFP-15/PIP/AQP5 axis may open novel scenarios for our 
understanding of salivary gland hypofunction in pSS.
Materials and Methods
Patients and experimental design
This study was approved by the ethics committee of our academic 
hospital. A total of 123 salivary samples from patients affected by pSS, 
no-SS sicca syndrome and sex- and age-matched healthy volunteers 
were collected consecutively from May 2012 to February 2013 at the 
Rheumatology Unit of the University of Pisa. The diagnosis of pSS 
was made according to the International Classification Criteria for 
the disease (AECG) [17] while the condition of no-SS sicca syndrome 
was defined as the presence of xerostomia in patients who did not 
meet the diagnostic AECG criteria for SS (non-SS sicca, CTL). To be 
included in the study all the subjects had to be at least 18 years old 
and able to provide a signed informed consent. According to the 
AECG, exclusion criteria for pSS patients included: past head and neck 
radiation treatment, hepatitis C infection, acquired immunodeficiency 
disease (AIDS), pre-existing lymphoma, sarcoidosis, Graft versus host 
disease, and use of anticholinergic drugs. Detailed medical charts were 
available for all patients. Variables analyzed in the study included: sex, 
age, time since diagnosis, subjective dry eyes and mouth, and parotid 
gland enlargement. Minor salivary gland (MSG) biopsy results were 
classified according to the focus scoring system. Patients’ treatments 
at the inclusion in the study were also recorded. At the time of the 
study entry, every patient had an evaluation of salivary flow rate, 
ophthalmological examination and autoantibody testing of the 
serum (i.e antinuclear antibodies, extractable nuclear antigen (ENA) 
antibodies, rheumatoid factor, anticentromere auto-antibodies (ACA), 
anti Scl-70, anti-cyclic citrullinated peptide (anti-CCP)). Salivary 
samples were collected under standard conditions and analyzed using 
different proteomic techniques (SELDI-TOF-MS, 2DE, MALDI-
TOF-MS). The data generated from the proteomic analysis were then 
validated by western blot analysis. This second validation phase also 
included the analysis by Real Time PCR and immunohistochemistry 
of the expression of GCDFP-15/PIP in the MSG biopsies obtained for 
diagnosis from subjects who had been newly diagnosed with pSS- or 
no-SS sicca syndrome (Figure 1).
Samples collection and processing
Saliva samples: Unstimulated whole salivary samples were 
collected between 9 and 11 a.m. from patients who had refrained from 
eating or drinking for 2 h following previously described procedures [7]. 
Immediately after the collection and salivary flow rates determination 
in order to minimize the degradation of the proteins, the samples 
were processed immediately and kept on ice during the entire process. 
Samples were immediately centrifuged at 13.000 x g for 20 minutes 
at 4°C to remove debris and cells, and protein amounts of resulting 
supernatants were determined using Protein Assay dye reagent (Bio-
Rad; Richmond, CA). Aliquots of the samples were stored at -80°C 
until analysis.
Minor salivary gland biopsy samples: Minor salivary glands 
(MSGs) were obtained as part of routine diagnostic procedures when 
pSS was suspected. MSG biopsies were performed after local anesthetic 
infiltration. In all the cases, the MSG specimens from each subject were 
divided and some were fixed in neutral buffered formalin for the focus 
score assessment, and the rest were snap frozen and stored at -80°C. 
All of the MSG formalin-fixed specimens were processed (paraffin 
embedding, sectioning and hematoxylin and eosin staining) and 
evaluated by the same pathologist. If a diagnosis of focal lymphocytic 
sialoadenitis was made, the focus score was then determined according 
to the scoring guidelines [18]. The frozen sample was employed for the 
Real time PCR analysis.
SELDI-TOF analysis
The ProteinChip System, Series 4000 Personal Edition (Ciphergen 
Biosystems, Inc) was used to perform SELDI-TOF MS. After 
preliminary experiments with different protein chip arrays (including 
Q10, IMAC30 and H50, Bio-Rad), the cation exchange array CM10 
(Bio-Rad) - a weak cation exchange chip - was selected to give the best 
results and prepared according to the manufacturer’s instructions. 
Briefly, 20 μg of proteins, previously treated with 2/3 (v/v) denaturing 
buffer (CHAPS 2%, Urea 9M) were directly applied to each Protein 
Chip array spot. The experiment was conducted as previously described 
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Figure 1: Flow chart of the patients’ enrolled in the study (2DE, 2D 
electrophoresis; WB, western blot; MSGB, minor salivary gland biopsies; IHC, 
immunohistochemistry).
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[19,20]. Chips were read on a Ciphergen Express Data Manager – 
Personal Edition (version 3.5). 
2DE analysis and mass spectrometry analysis
Two-dimensional electrophoresis (2DE) was performed using the 
Immobiline-polyacrylamide system with pH 3-10L, 17 cm IPG strips 
(Protean IEF Cell, Bio-Rad). The second dimension (SDS-PAGE) was 
performed using 15% polyacrylamide gels, maintained at 12°C. The 
analytical gels were stained with colloidal Coomassie Silver Blue [21] 
and scanned using the GS800 Densitomer (Bio-Rad). Subsequently, 
the gels were analyzed with the PDQuest advanced software. Spots 
of interest were cut out from the master gel and MALDI-TOF mass 
spectrometry technique was used to identify the spots of interest, cut 
out from the master gel as previously described [6,7]. In-gel digestion 
and mass spectrometric (MS) analyses were performed at the Mass 
Spectrometry Facility (Biotechnology Center, University of Wisconsin-
Madison) as outlined on the Center website, as previously described 
(http://www.biotech.wisc.edu/ServicesResearch/MassSpec/ingel.htm). 
Western blot analysis
Western Blot (WB) analysis was used validate the 2DE results. We 
employed the Stain-Free technology which has recently demonstrated 
to be a more reliable, more robust, and more sensitive normalization 
tool for WB experiments when compared to traditional housekeeping 
protein (HKP) normalization [22]. More specifically, one-dimensional 
SDS-electrophoresis was first performed. Briefly, aliquots of all 
saliva samples (30 μg of total protein) were treated with Laemmli 
buffer and heated at 100°C for 5 minutes, loaded on 4-20% Mini-
PROTEAN TGX Stain-Free (#456-8093, Bio-Rad), and run for 30 
minutes at 200 V, according to manufacturer’s instructions. After 
electrophoresis, stain-free gels underwent UV activation, as previously 
described [22] in order to assess protein transfer after blotting (total 
protein volume acquired from each lane by ChemiDoc, Bio-RAD). 
WB was subsequently performed, as previously described [23], using 
an N-terminal monoclonal anti-human GCDFP-15/PIP antibody 
(Abcam; Cambridge, UK) as primary antibody. The chemiluminescence 
expressed in terms of volume of specific immunoreactive bands was 
determined (ChemiDoc, Bio-Rad), and normalized to the total protein 
volume previously acquired. Each value was then normalized on an 
internal control sample (the same for every gel) treated in the same 
experimental conditions, in order to compare samples which run in 
different gels.
RNA extraction and pPCR
Total RNA was extracted from frozen minor salivary gland biopsy: 
tissues were disrupted and homogenized through high-speed shaking 
with beads (Qiagen) using the TissueLyser (Qiagen) and RNA was 
purified by miRCURY RNA Isolation kit (EXIQON) according to 
manufacturer’s instructions. The RNA reverse-transcription was 
carried out using 500 ng of total RNA using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Taqman Probe for 
the GCDFP-15/PIP mRNA and GAPDH mRNA were used (part no. 
Hs00160082_m1 and part no. Hs02758991_g1, respectively). Real 
Time PCR was performed in triplicate on an Eco real time instrument 
(Illumina Inc) following the standard protocol. Transcripts were 
evaluated by TaqMan Gene Expression Assays (Applied Biosystems): 
20ul PCR was run with cycling conditions of 10 minutes at 95°C, 
followed by 40 cycles of denaturing for 15 seconds at 95°C, and 
annealing and extending for 60 seconds at 60°C. Amplifications were 
normalized by GAPDH (Hs02758991_g1) and quantitation of gene 
expression was performed using the ΔΔCT calculation, where CT is the 
threshold cycle. The amount of the target gene normalized and relative 
to the calibrator (control sample) is given as 2- 2- ΔΔCT.
Immunohistochemistry analysis
Rehydrated 5-µm paraffin sections of formalin-fixed salivary gland 
biopsies, were pretreated using high temperature antigen retrieval in 
Citrate buffer 0.01M, pH 6 for 15 min at 80% power, and brought it to 
RT for 15 min. An incubation of 20 min in 100 mM glycine at RT was 
used to block the free aldehydes. To block nonspecific binding 10% 
FBS, 0.4% saponin, 0.02% NaN3 in PBS in PBS buffer pH 7.4 was used. 
The sections were incubated with the primary antibody anti- GCDFP15 
(ab62363, Abcam) diluted in blocking buffer 1/200 overnight at 4°C. 
For the secondary fluorescence-labeled antibodies, 1:300 dilution of 
AlexaFluo 488-conjugated (red) or Alexa 594–conjugated (green) 
antibodies were used (Jackson Immuno Research; West Gorve, PA). 
The bands were visualized with Histostain®-Plus 3rd Gen IHC Detection 
Kit (Invitrogen, CARLSBAD, CA) according to the manufacturer. For 
nuclear counterstain Mayer’s Hematoxylin was used. Finally the slides 
were coversliped using CitraMount medium (Electron Microscopy 
Hatfield, PA).
Statistical analysis
SELDI_TOF_MS data analysis and CART algorithm: On the 
basis of their distributional assumptions, SELDI-TOF-MS data were 
analyzed by using a non-parametric approach which was carried out by 
Mann-Whitney test for univariate analysis coupled with a classification 
and regression tree (CART) algorithm in the multivariate setting. Only 
significant variables (p<0.05) at the univariate analysis were included 
in the CART algorithm. 
The construction of CART included two steps, namely the tree 
construction step and the tree pruning step. For the tree construction 
process, the best peak was searched with defined cut-off level so that 
the dataset was split into two daughter nodes. The splitting decision 
was based on the peak intensity of a sample. Samples went to the left 
daughter node if their peak intensities were equal to or less than the 
cut-off intensity value; otherwise, the samples would go to the right 
daughter node. instead of Samples went to the left daughter node if 
their peak intensities were equal to or less than the cut-off intensity 
value; otherwise, the samples would go to the right daughter node. The 
software continued to repeat this splitting process on each daughter 
node in this manner until no further gain in the classification was 
achieved and terminal nodes were produced. Classification of the 
terminal nodes was decided by a group of samples, which represented 
the majority of samples in that group. In the second step of CART, 
the classification tree was cut down to a desired size that yielded the 
least classification error. The best among all pruned trees were selected 
on the basis of the minimization of the leave one out cross validation 
error. Statistical analysis was performed by using” R: A language and 
environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org/.”
Statistical analysis of WB and qPCR results
Continuous data were expressed as median and interquartile range. 
Statistical analyses of the results were carried out using the χ2 test and 
the Mann–Whitney test. Spearman’s rank correlation coefficient was 
employed in order to correlate subjects’ clinical parameters with the 
normalized values of band intensity from Western blot and the log 
of RQ values from RT-PCR. In addition a Semi-Quantification of the 
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normalized values of GCDFP-15/PIP band intensity from Western 
blot (normal or low) was also obtained using the minimum value of 
GCDFP-15/PIP expression level of normal controls as a cut-off point. 
The p-values <0.05 were considered significant. Statistical analysis 
software SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis.
Results
Patients
Unstimulated whole saliva samples were collected from 89 
consecutive unselected female patients with pSS (age at inclusion, 
mean (SD) = 54.6 yrs (13.8 yrs) and from 29 sex- and age- matched 
HC (age at inclusion, mean (SD) = 53.2 yrs (12.8 yrs)) and analyzed 
using complementary proteomic techniques (i.e. SELDI-TOF-MS 
and 2DE/MALDI-TOF-MS) (Figure 1). Unstimulated whole salivary 
flow rates of the groups (median and IQR) were 2 ml/15 min (1.1 to 
4.125 ml/15min) and 4.15 ml/15 min (2.5 to 7.875 ml/15 min) for pSS 
patients and HC, respectively (p=0.001). Of the 89 pSS patients, 30/89 
was newly diagnosed with pSS: these patients were included also in the 
second phase of the study and their MSG biopsies were collected and 
analyzed as well. The control group for this second phase of the study 
consisted of 15/29 HC and 12 no-SS sicca syndrome subjects, both 
recruited during the same period of the 30 pSS patients (Figure 1). All 
the no-SS sicca syndrome subjects underwent MSG biopsy. Subjects’ 
demographic and clinical features are summarized in Table 1.
SELDI-TOF MS results
A total of 75 peaks were detected. Peak values were generated for 
each sample. Mean peak intensities of the groups were compared by 
Mann Whitney test at the univariate analyses. We found that 25 peaks 
were significantly different in the pSS patient group with respect to non-
SS (p<0.05). Among these 25 peaks, the selected CART tree indentified 
7149 m/z (v34), 7192 m/z (v35), 13507 m/z (v54), 13714 m/z (v55), 
16547 m/z (v63), 24059 m/z (v66) as best independent biomarkers able 
to discriminate between pSS and HC with a sensitivity of 96 % and a 
specificity of 70%, with a global cross validated error of 29% (Figure 2). 
Identification of GCDFP-15/PIP protein
We specifically focused on the 16547 m/z peak, which splitting the 
dataset in two daughter nodes yielded the least classification error. This 
peak was significantly reduced in pSS vs HC (p<0.0001). We thought 
that this 16547 m/z peak might be potentially related to GCDFP-15/
PIP protein (calculated mass 16572 Da) which has been previously 
described as significantly decreased in pSS saliva. In order to verify 
our hypothesis we compared SELDI-TOF MS and 2DE results for 
the same salivary samples as in previous studies [20,24]. 2DE analysis 
was performed with 3 salivary samples from each of the two groups 
(pSS and HC) and the identification of the putative spots related to the 
GCDFP-15/PIP protein was performed by MALDI-TOF-MS (mascot: 
http://www.matrixscience.com/: accession no. P12273; Nominal mass 
(Mr): 16562; calculated pI value: 8.26; sequence coverage: 46%; score 
229). We obtained similar profiles in SELDI analyses and in the 2DE 
for each of the samples tested (Figure 3).
Western Blot analysis
In order to further validate our work hypothesis and to better 
investigate the diagnostic role of GCDFP-15/PIP as putative diagnostic 
biomarker, we assessed the salivary expression levels of GCDFP-15/
PIP by WB in patients newly diagnosed with pSS, HC and in patients 
of the sicca group no-SS sicca who had been recruited during the same 
time period of pSS patients. 
Comparison between the pSS group and control groups disclosed 
that the intensity of GCDFP-15/PIP was significantly lower in pSS 
patients when compared to both no-SS sicca subjects and HC using 
Anova test and Bonferroni correction post-hoc test (p<0.0001). Figure 
4 shows a representative WB of GCDFP-15/PIP on salivary protein 
extract, while the Figure 5 represents the Boxplot of GCDFP-15/
PIP expression measured by WB in the three groups (median and 
interquartile range). We also found that GCDFP-15/PIP expression 
correlated with both the salivary flow rate (r=0.312, p=0.023) and MSG 
biopsy focus score (r=-0.377, p=0.04). 
Using the minimum value of GCDFP-15/PIP expression level of 
normal controls as a cut-off point we obtained a semiquantification 
of the GCDFP-15/PIP protein levels measured by Western Blot. This 
allowed us not only to confirm the different expression of GCDFP-15/
PIP proteins between the groups (p<0.0001) but also to correlate 
GCDFP-15/PIP levels with some of the subjects clinical features. More 
specifically we found that the decrease of GCDFP-15/PIP salivary 
expression was directly correlated with both the reduction of the salivary 
flow rate (p=0.002) and with the focus score of the MSGBs (p=0.023). 
Figure 6 shows the Boxplot of the salivary flow rate when patients 
were separated into two groups according to their WB expression 
level of GCDFP-15/PIP (normal or low), using the minimum value of 
expression level of normal controls as a cut-off point.
mRNA GCDFP-15/PIP in MSGs
To investigate whether the mRNA level of GCDFP-15/PIP were 
lower in PSS than in the sicca group according to the protein level trend, 
real-time PCR was conducted on the RNA extracted from salivary 
gland biopsies. 23 pSS and 11 control salivary gland biopsies were lysed 
and total RNA exctracted and retrotrascribed. The mRNA levels of 
GCDFP-15/PIP were normalized to GAPDH mRNA level. Comparison 
First phase of the study Second phase of the study
pSS (n=82) HC (n=29) p-value pSS (n=30) HC (n=15) Non-SS (n=12) p-value
Sex 82F 29F 30F 15F 12F
Age at the inclusion (yrs), mean (SD) 54.6 (13.8) 53.2 (12.8) n.s. 53.9 (12.7) 52.6 (12.4) 54.0 (13.4) n.s.
Salivary flow rate ml/15’
(median and interquartile)
(mean(SD))
2(1.1 to 4.125)
3.0(2.7)
4.15(2.5 to 7.875)
5.3(3.7) 0.005 2.5(1.5 to 4.25)
5.5(4.2 to 10)
5.1(4.2)
3(2.1 to 6.75)
6.6(3.1) 0.013
Focus score (high/low) 20/50 n.a. n.a. 7/16 n.a. n.a. n.a.
ANA (%) 100 n.a. n.a. 100 n.a. 58 0.0009
Anti-Ro/SSA (%) 57.3 n.a. n.a. 60 n.a. n.a. n.a.
Anti-La/SSB (%) 22 n.a. n.a. 18 n.a. n.a. n.a.
Rheumatoid Factor (%) 43 n.a. n.a 43 n.a. n.a. n.a.
Table 1: Patients’ demographic and clinical features (SD, standard deviation; F, female; n.s., not significant; n.a., not applicable, ANA, anti-nuclear antibodies).
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of the GCDFP-15/PIP mRNA level between the pSS group and the 
control groupshowed that GCDFP-15/PIP mRNA was significantly 
lower in pSS patients when compared to no-SS sicca subjects using 
Mann Whitney post hoc test (p=0.023). Figure 7 represents the Boxplot 
of GCDFP-15/PIP expression measured by pPCR in the two groups 
(median and interquartile range). We also found that GCDFP-15/PIP 
mRNA expression correlated with both the salivary flow rate (r=0.676, 
p=0.002) and MSGBs’ focus score (r=-0.379, p=0.03).
Immunohistochemistry
Immunohistochemical studies of GCDFP-15/PIP in sections 
derived from pSS biopsies andno-SS sicca controls, showed that the 
Figure 2: Classification and regression tree (CART) algorithm, as result of the 
analysis of the SELDI-TOF-MS results (SS, Sjögren’s syndrome; HC, healthy 
control, V63=16547 m/z, V66=24059 m/z, V54=13507 m/z, V55=13714 m/z, 
V34=7149 m/z, V35=7192 m/z).
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Figure 3: Representative 2DE - gel map from a) primary Sjögren’s syndrome 
patient b) healthy control.
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Figure 4: Median and interquartile range of GCDFP-15/PIP optical density of 
patients and healthy controls (p<0.0001 by ANOVA analysis). GCDFP-15/PIP 
is differently expressed between primary Sjögren’s syndrome patients (pSS) 
and non-SS sicca syndrome patients (CTL), with p=0.01 (*), and between 
pSS and healthy control subjects (HC), with p<0.0001 (***).
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Figure 5: Representative Western blot comparative analysis between 
Sjögren’s syndrome patients (pSS), non-SS sicca syndrome patients (CTL), 
and healthy control subjects (HC). a) acquisition of total protein content run 
during 1D SDS-electrophoresis, after the stain-free gel was UV-activated; b) 
acquisition of immunoreactive GCDFP-15/PIP band on a nitrocellulose film.
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Figure 6: Difference of salivary flow rate between patients with low versus 
normal GCDFP-15/PIP expression, as result of a qualitative western blot 
analysis, obtained by using the minimum value of GCDFP-15/PIP expression 
level of healthy controls as a cut-off point to discriminate between a low and a 
normal expression (Mann Whitney test, p=0.0022).
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staining of GCDFP-15/PIP is located intracellular in mucus and serous 
acinar cells (Figure 8). In controls the staining is more concentrated 
towards the apical pole of mucous cells (marked with m in Figure 
8A’) and ductal cell are negative. In some cases it is also possible to 
observe some immunoreactive material in the lumen of major ducts 
(asterisk in Figure 8A). Compared to the controls, in SS patients the 
immunoreactivity for GCDFP-15/PIP is faint in mucous acini (m in 
Figure 8B’) and no major differences were observed in serous acinar 
cells (Figure 8B). 
Discussion
This study, integrating emerging and complementary techniques, 
allowed us to investigate, simultaneously in saliva and in MSG biopsies, 
the potential role of GCDFP-15/PIP as a novel biomarker for pSS. We 
first demonstrated by SELDI-TOF-MS that a 16547 m/z peak was the 
best independent biomarker for pSS yielding the least global cross 
validated error with a good sensitivity and specificity. SELDI-TOF-
MS technique does not allow a direct identification of any putative 
peak/biomarker but only indirect identifications. Thus, we decided 
to verify the potential correspondence between the 16547 m/z peak 
and GCDFP-15/PIP protein since, among all the candidate proteins, 
GCDFP-15/PIP was the closest in terms of molecular weight to the 
detected peak and it has been previously described as significantly 
reduced in pSS. The parallel analysis of the same salivary samples by 
SELDI-TOF-MS and 2DE/MALDI-TOF-MS strongly supported our 
work hypothesis and encouraged the subsequent validation of the 
results obtained in this first part of the study. Therefore, we validated 
by WB analysis the expression of GCDFP-15/PIP in the subgroup of 
patients newly diagnosed with pSS and we confirmed that GCDFP-15/
PIP was significantly reduced in pSS patients compared to healthy 
controls and with those subjects originally suspected to have pSS who, 
at the end of the diagnostic algorithm, were diagnosed as no-SS sicca 
syndrome. 
In the subgroup of patients newly diagnosed with pSS we were 
also able to assess both the glandular expression of the GCDFP-15/PIP 
and the levels of glandular GCDFP-15/PIP mRNA in MSG biopsies. 
We verified that in pSS GCDFP-15/PIP staining was faint in mucous 
acini and that the observed reduction of GCDFP-15/PIP in saliva was 
related to a decrease in the protein production rather than to an altered 
release of the protein. From this point of view, it is noteworthy that the 
mRNA levels of GCDFP-15/PIP and the salivary levels of the protein 
correlated with both the MSG biopsy focus score and the patients’ 
salivary flow rate. These results allowed us to speculate that the 
observed GCDFP-15/PIP salivary reduction may closely mirror pSS 
lymphocytic-mediated acinar damage and consider the hypothesis that 
the impairment of the AQP5-GCDFP-15/PIP axis might have a role in 
pSS glandular dysfunction [25-28]. The analysis of AQP5 distribution 
in MSG biopsies from pSS patients and controls was beyond the aims 
of this study. However, our results provide evidence which suggests 
that the production of GCDFP-15/PIP is significantly reduced in pSS 
making this protein a putative candidate biomarker for pSS diagnosis 
and shedding new light on the possible pathophysiological role of the 
protein in pSS exocrinopathy. 
Taken together, these findings encourage further research in 
large clinical studies aimed at defining individual cut-off values for 
GCDFP-15/PIP protein as a novel salivary diagnostic biomarker for pSS. 
It is likely that once GCDFP-15/PIP abnormal levels will be defined, the 
protein could be routinely measured by less expensive procedures and 
might provide physicians with feasible information about the disease 
state improving patients’ overall diagnostic assessment.
In summary , this study represents a step forward in the direction 
of the search for novel reliable, early and non-invasive diagnostic 
biomarkers in autoimmune diseases through the extensive integration 
of genomic and proteomic studies. The expression of GCDFP-15/
PIP was apparently able to reflect both the anatomical damage and 
the functional impairment of the salivary glands in pSS. Thus, further 
studies are warranted in order to better investigate the implication 
of the axis GCDFP-15/PIP /AQP5 on the pathogenesis of pSS sicca 
syndrome. Hypothetically, GCDFP-15/PIP might represent not only 
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Figure 7: Difference of mRNA expression (GCDFP-15/PIP mRNA expression 
normalized on GAPDH) between patients with primary Sjögren’s syndrome 
(pSS) and no-SS sicca syndrome subjects (CTL) (Mann Whitney test, 
p=0.023).
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Figure 8: Immunohistochemical studies of GCDFP-15/PIP in sections derived 
from SS biopsies and healthy volunteer. In healthy volunteer the staining is 
more concentrated towards the apical pole of mucuse cells (acinous marked 
with m in figure 8A’) and ductal cell are negative, is also possible observe 
some immunorective material in the lumen of mayor ducts (asterisk in figure 
8A). In SS patients the immunoreactivity for GCDFP-15/PIP is faint in mucus 
acini (see m in figure 8B’), no major changes were observed in serous acinar 
cells but slightly increase in the intensity of the immunoreactivity in this cells.
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novel putative early non-invasive diagnostic biomarkers for the disease 
but also a novel specific target for gene therapy.
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